•  

     

    NEWS

    The most relevant news about our Group, in Argentina and around the world.

Making available free paediatric medicine can accelerate elimination of congenital Chagas disease

The donation of an essential antiparasitic medicine can potentially accelerate the elimination of Chagas disease infection in children. A pediatric presentation of benznidazole with accurate dosage and will soon be made available freely to address a long-standing gap in the treatment of congenital infections of Chagas disease.  

The donation, by the Mundo Sano Foundation1 and INSud Pharma2 group to the World Health Organization (WHO), is expected to become effective soon.

Chagas disease

The donation, by the Mundo Sano Foundation and INSud Pharma group to the World Health Organization (WHO), is expected to become effective soon.

“Making benznidazole freely available for the treatment of newborns and children until the age of 19 will be a game-changer in the fight against Chagas disease” said Dr Mwelecele Ntuli Malecela, Director, WHO Department of Control of Neglected Tropical Diseases. “This can save future generations from developing life-threatening and fatal complications and also boost up diagnosis and treatment contributing to congenital Chagas disease elimination.”

The three-year agreement will make available 108 000 tablets of benznidazole3 – one of the two antiparasitic medicines against Chagas disease. Treatment4 with benznidazole in the early stages of infection can cure Chagas disease, prevent or curb disease progression and prevent congenital transmission in pregnant women.

 “We have now added the systematic detection and treatment of all newborns and children under 19 which was not part of  our recent switch from control to elimination of congenital Chagas disease” said Dr Pedro Albajar Vinas, Medical Officer, WHO Department of Control of Neglected Tropical Diseases. “In addition, screening of pregnant women at risk of infection who have not had past antiparasitic treatment provides an excellent opportunity for prevention of posterior transmission throughout pregnancy and birth.”

Each year, an estimated 15 000 children are born from infected mothers. 

The agreement

The donation by Mundo Sano Foundation for the duration of the agreement comprises benznidazole:

  • 105,000 tablets of 100mg
  • 3,000 tablets of 12.5mg

Furthermore, the Foundation may donate funds to support activities associated with distribution of medicines and is ready to consider extending this agreement beyond the specified duration of three years.

The disease

Chagas disease, also known as American trypanosomiasis, is a potentially life-threatening illness caused by the protozoan parasite Trypanosoma cruzi (T. cruzi).

Although considerable progress has been achieved, particularly in reducing vector transmission and screening of blood and organ supply, reaching, diagnosing and providing healthcare for people most affected has been a challenge.

Currently, under-diagnosis of Chagas disease cases is as high as 90% and under-diagnosis of congenital and paediatric cases is believed not to be lower.

Globally, an estimated 6-7 million people are infected with T. cruzi.

The disease is found mainly in endemic areas of 21 continental Latin American countries5. But movement of people to urban areas and to other continents has expanded its transmission through non vectorial routes, such as blood transfusion, congenital transmission, organ transplants and oral transmission through food contamination.

Considering that neglected tropical disease as a growing public health problem in many countries, the World Health Assembly – WHO’s decision-making body – decided in May 2019 to commemorate World Chagas Disease Day on 14 April.

The inaugural celebration happens this year.


1Mundo Sano is a nonprofit international foundation working with the public and private sectors, academia, and other international organizations to provide solutions to the affected communities and generate scientific knowledge. In 2012, it led a public-private consortium in 2012 to produce benznidazole in Argentina.

2Insud Pharma (formerly known as Chemo Group) specializes in research, development, manufacture, sale and marketing of active pharmaceutical ingredients and medicinal products for human and veterinary use.

3In 2017, the United States Food and Drug Administration (FDA) approved benznidazole for the treatment of children aged 2–12, making it the first treatment approved in the United States for Chagas disease.

4Nifurtimox is also 100% effective in curing Chagas disease if given soon after onset of infection, including cases of congenital infection. It is donated by Bayer who pledged more than 7.5 million tablets for the period 2012-2021.

5Argentina, Belize, Bolivia (Plurinational State of), Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, French Guiana, Guatemala, Guyana, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Suriname, Uruguay, and Venezuela (Bolivarian Republic of).

Nota original

Top Story

News

Entrepreneur Of The Year: Silvia Gold, una de las premiadas por su desempeño

Silvia Gold, doctora en Bioquímica y co-fundadora de Grupo Insud, recibió el galardón a la Trayectoria Empresarial. El programa Entrepreneur Of The Year reconoce los esfuerzos de mujeres y hombres excepcionales que crean los productos y servicios que hacen que … Continue reading

+

Latest News

News Grupo Insud

Hugo Sigman adelantó avances en investigaciones sobre dos tratamientos contra el COVID-19: Ivermectina y suero hiperinmune

+

News Uncategorized

Hugo Sigman en “Para que el día después seamos mejores – Construyendo consensos para la acción”

+